BR9909266A - Formulações efervescentes - Google Patents

Formulações efervescentes

Info

Publication number
BR9909266A
BR9909266A BR9909266-2A BR9909266A BR9909266A BR 9909266 A BR9909266 A BR 9909266A BR 9909266 A BR9909266 A BR 9909266A BR 9909266 A BR9909266 A BR 9909266A
Authority
BR
Brazil
Prior art keywords
alkali
effervescent
sensitive active
formulations
effervescent formulations
Prior art date
Application number
BR9909266-2A
Other languages
English (en)
Inventor
Wolfram Tritthart
Maria Andre Maildorf Piskernig
Gottfried Koelbl
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of BR9909266A publication Critical patent/BR9909266A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçõES EFERVESCENTES"<D>. A invenção refere-se a formas de preparação rapidamente decomponíveis para substâncias ativas sensíveis a álcali, particularmente selegilina para emprego oral na forma de formulações efervescentes que contêm uma substância ativa sensível a álcali e uma base efervescente consistindo em um ou mais carbonatos alcalino-terrosos, um ácido orgânico comestível e/ou um sal alcalino do ácido cítrico, e opcionalmente coadjuvantes farmaceuticamente empregáveis.
BR9909266-2A 1998-03-31 1999-03-20 Formulações efervescentes BR9909266A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814257A DE19814257A1 (de) 1998-03-31 1998-03-31 Brauseformulierungen
PCT/DE1999/000798 WO1999049842A1 (de) 1998-03-31 1999-03-20 Brauseformulierungen

Publications (1)

Publication Number Publication Date
BR9909266A true BR9909266A (pt) 2000-11-21

Family

ID=7863015

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909266-2A BR9909266A (pt) 1998-03-31 1999-03-20 Formulações efervescentes

Country Status (29)

Country Link
US (1) US6242002B1 (pt)
EP (1) EP1067905B1 (pt)
JP (1) JP4469494B2 (pt)
KR (1) KR100607395B1 (pt)
CN (1) CN1138529C (pt)
AR (1) AR018829A1 (pt)
AT (1) ATE224703T1 (pt)
AU (1) AU753194B2 (pt)
BG (1) BG65043B1 (pt)
BR (1) BR9909266A (pt)
CA (1) CA2326502C (pt)
CZ (1) CZ300705B6 (pt)
DE (2) DE19814257A1 (pt)
DK (1) DK1067905T3 (pt)
ES (1) ES2183555T3 (pt)
HK (1) HK1036010A1 (pt)
HU (1) HU229793B1 (pt)
IL (1) IL138605A (pt)
NO (1) NO329143B1 (pt)
NZ (1) NZ506989A (pt)
PL (1) PL192049B1 (pt)
PT (1) PT1067905E (pt)
RU (1) RU2221554C2 (pt)
SK (1) SK284477B6 (pt)
TR (1) TR200002812T2 (pt)
TW (1) TW580398B (pt)
UA (1) UA66847C2 (pt)
WO (1) WO1999049842A1 (pt)
ZA (1) ZA200005133B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
AU2007203233B2 (en) * 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
AU2004242477B2 (en) * 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
IL151888A0 (en) * 2000-03-28 2003-04-10 Biochemie Gmbh Granulated particles with masked taste
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040175456A1 (en) * 2003-03-06 2004-09-09 Lauren Keilbach Tablets for feeding fish and methods of making tablets for feeding fish
US20040191298A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
MXPA06007453A (es) * 2003-12-31 2007-01-31 Cima Labs Inc Forma de dosificacion de opiaceo oral efervescente.
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
JP2007517054A (ja) * 2003-12-31 2007-06-28 シーマ・ラブス、インコーポレイテッド 概して線状の発泡性経口フェンタニル投薬形態および投与方法
US7033511B2 (en) 2004-01-20 2006-04-25 A-Dec, Inc. Sustained water treatment in dental equipment
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
WO2007026864A1 (ja) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. 崩壊性の改善された医薬組成物の製造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP3449928A1 (en) * 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
RU2011119494A (ru) * 2008-10-14 2012-11-27 Макнейл Аб Многокомпонентная интраоральная лекарственная форма препарата и ее применение
KR101233352B1 (ko) * 2009-04-22 2013-02-25 (주)비씨월드제약 유전자 재조합 과립구-대식세포 집락 촉진인자를 함유하는 정제
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
MX2014009247A (es) 2012-02-01 2014-10-14 Intercontinental Great Brands Llc Tableta para bebida baja en calorias.
WO2014098176A1 (ja) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
MX2017001980A (es) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y metodo para su produccion.
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP6757959B2 (ja) 2015-06-16 2020-09-23 株式会社 PRISM BioLab 抗がん剤
CN109303334B (zh) * 2018-10-17 2021-04-13 汤臣倍健股份有限公司 一种口腔微泡腾片及其制备方法
ES2945809T3 (es) * 2019-10-02 2023-07-07 Intas Pharmaceuticals Ltd Composiciones farmacéuticas sólidas efervescentes prácticamente sin sodio
WO2021239541A1 (en) * 2020-05-28 2021-12-02 Unilever Ip Holdings B.V. Tablet

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
DE3440288A1 (de) * 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
HU209605B (en) 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
ES2074769T3 (es) 1991-07-01 1995-09-16 Gergely Gerhard Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.
EP0592484B1 (de) 1991-07-01 1995-01-18 Gergely, Gerhard, Dr. Reaktionsdotierte brausesysteme
EP0593807A1 (en) 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH &amp; Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
AU672617B2 (en) 1992-06-22 1996-10-10 Regents Of The University Of California, The Glycine receptor antagonists and the use thereof
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
FR2698788B1 (fr) * 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
CA2153243A1 (en) * 1993-01-27 1994-08-18 Harold E. Selick Compositions and methods for transdermal drug delivery
US5287394A (en) 1993-03-22 1994-02-15 Advanced Micro Devices, Inc. Fast counter with uniform delay structures
SE9301112D0 (sv) 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
DE59400446D1 (de) * 1993-04-15 1996-08-29 Gergely Gerhard Brausesystem mit einem alkali- und/oder metallempfindlichen, pharmazeutischen Wirkstoff, und Verfahren zur Herstellung
DK0813865T3 (da) 1993-04-20 2001-11-19 Hexal Ag Plaster med virksomt stof
US5503844A (en) * 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
AU677432B2 (en) 1993-09-09 1997-04-24 Gerhard Gergely Effervescent granulated material and method for its preparation
CN1082828C (zh) 1993-11-12 2002-04-17 杰哈德·盖尔盖伊 制备粒状材料的方法
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
US5603955A (en) 1994-07-18 1997-02-18 University Of Cincinnati Enhanced loading of solutes into polymer gels
HU223475B1 (hu) 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
DE29500718U1 (de) * 1995-01-18 1995-04-06 Rau, Reinhard, 37242 Bad Sooden-Allendorf Element einer Zeltplane zum Aufbau von kohten- und jurtenähnlichen Zeltaufbauten
EP0866691B2 (en) 1995-11-06 2005-01-26 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline

Also Published As

Publication number Publication date
PT1067905E (pt) 2003-02-28
NZ506989A (en) 2002-09-27
HK1036010A1 (en) 2001-12-21
ATE224703T1 (de) 2002-10-15
RU2221554C2 (ru) 2004-01-20
HUP0101427A2 (hu) 2001-08-28
HU229793B1 (en) 2014-07-28
DE59902843D1 (de) 2002-10-31
BG104841A (en) 2001-07-31
CA2326502A1 (en) 1999-10-07
WO1999049842A1 (de) 1999-10-07
SK14322000A3 (sk) 2001-07-10
UA66847C2 (uk) 2004-06-15
JP4469494B2 (ja) 2010-05-26
CZ20003482A3 (en) 2001-05-16
CA2326502C (en) 2008-08-05
US6242002B1 (en) 2001-06-05
NO329143B1 (no) 2010-08-30
BG65043B1 (bg) 2007-01-31
ES2183555T3 (es) 2003-03-16
PL343260A1 (en) 2001-07-30
PL192049B1 (pl) 2006-08-31
DK1067905T3 (da) 2003-02-03
IL138605A0 (en) 2001-10-31
NO20004721D0 (no) 2000-09-21
SK284477B6 (sk) 2005-04-01
IL138605A (en) 2005-11-20
CZ300705B6 (cs) 2009-07-22
TW580398B (en) 2004-03-21
AR018829A1 (es) 2001-12-12
HUP0101427A3 (en) 2001-12-28
AU4029499A (en) 1999-10-18
CN1138529C (zh) 2004-02-18
ZA200005133B (en) 2001-02-28
KR100607395B1 (ko) 2006-08-02
JP2002509872A (ja) 2002-04-02
EP1067905A1 (de) 2001-01-17
AU753194B2 (en) 2002-10-10
TR200002812T2 (tr) 2001-01-22
EP1067905B1 (de) 2002-09-25
DE19814257A1 (de) 1999-10-07
CN1295463A (zh) 2001-05-16
NO20004721L (no) 2000-09-21
KR20010042317A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
BR9909266A (pt) Formulações efervescentes
DE69942921D1 (de) Osmotische Dosierungsform mit verlängerter Wirkstoffabgabe
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
ATE253896T1 (de) Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
BRPI0406996A (pt) Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização
AR018828A1 (es) Formulaciones efervescentes solidas de rapida desintegracion para administracion oral.
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
DE69233130D1 (de) Kaubare zusammensetzung zur arzneimittelfreisetzung
IL165601A0 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
ATE529097T1 (de) Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
AR036937A1 (es) Tableta masticable que contiene lisina
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
ATE318575T1 (de) Orale zubereitung chlorhexidin und maltitol oder erythritol oder deren mischung enthaltend
AR087240A2 (es) Composiciones farmaceuticas que tienen epinastina y pseudoefedrina
DE60006000D1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung
AR020205A1 (es) Formulacion efervescente esterilizante.
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
AR014082A1 (es) Concentrado oral de sertralina
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid

Legal Events

Date Code Title Description
TC Change of name
PC Transfer

Owner name: ASTA MEDICA HEALTH PRODUCTS GMBH & CO. KG (DE)

TC Change of name
B25G Requested change of headquarter approved

Owner name: VIATRIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050037237/RJ DE 17/05/2005.

B25D Requested change of name of applicant approved

Owner name: MEDA PHARMA GMBH AND CO. KG (DE)

Free format text: ALTERADO DE: VIATRIS GMBH AND CO. KG

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.